



# Follow-Up after High-Intensity Care or Substance Use Disorder (FUI)

HEDIS® Measurement Year 2024

**Measure description:** The percentage of acute inpatient hospitalizations, residential treatment, or withdrawal management visits for a diagnosis of substance use disorder among members 13 years of age and older that result in a follow-up visit or service for substance use disorder. Two rates are reported:

- Follow-up for substance use disorder within the 30 days after the visit or discharge
- Follow-up for substance use disorder within the 7 days after the visit or discharge

## Opioid Use Disorder Treatment Medications

- Naltrexone (oral and injectable)
- Buprenorphine (sublingual tablet, injection, implant)
- Buprenorphine/naloxone (sublingual tablet, buccal)

## Alcohol Use Disorder Treatment Medications

- Disulfiram (oral)
- Naltrexone (oral and injectable)
- Acamprosate (oral and delayed-release tablet)

## Strategies for Improvement

- Discuss the importance of timely, recommended follow-up visits.
- Coordinate care between Behavioral Health and Primary Care Physicians (e.g., share progress notes and updates and include diagnosis for SUD).
- Reach out to patients who cancel appointments and assist them with rescheduling as soon as possible.
- Consider telemedicine visits when in-person visits are not available.
- Notify our Concurrent Review team of patient's aftercare information on the day of discharge